Latest From Vivus Inc.
Orexigen, one of just five biopharma companies with an obesity product on the market, has become concerned about its ability to stay in business. Even so, the misfortune of several firms hasn't dissuaded others, including Novo Nordisk, from investing in the potentially large weight-loss market.
The commercial contest between satiety-producing weight loss products and evolving pharmacological medicines looks set to intensify after encouraging top-line pivotal data for Gelesis' capsule.
The Danish diabetes specialist is forging ahead with pivotal trials for its latest GLP-1 offering semaglutide in obesity after highly impressive Phase II efficacy data, but is likely to take the biggest market share from its own product, Saxenda.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017
- Therapeutic Areas
- Gynecological, Urological
- Metabolic Disorders
- Respiratory, Pulmonary
- North America
- Parent & Subsidiaries
- Vivus Inc.
- Senior Management
Thomas B King, Interim CEO
Mark K Oki, CFO & Chief Accounting Officer
Deborah W Larsen, PhD, Chief Commercial Officer
John L Slebir, SVP, Bus. Dev. & General Counsel
Santosh T Varghese, MD, CMO
- Contact Info
Phone: (650) 934-5200
900 E. Hamilton Ave
Campbell, CA 95008
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.